Selpercatinib Receives Traditional Approval for RET Fusion–Positive Solid Tumors

Originally published by our sister publication Clinical Oncology NewsBy Natasha Albaneze, MPHSelpercatinib (Retevmo, Lilly) was granted approval by the FDA to treat locally advanced or metastatic RET fusion–positive solid tumors in patients at least 2 years of age who have received prior systemic treatment.figure { display:inline-block; margin:0.5em; border:thin silver solid; padding:0.5em; font-size:smaller; text-indent:0; }figure img { max-width:100%; height:auto; width:auto; display:blo